As of close of business last night, Thermo Fisher Scientific Inc.’s stock clocked out at $584.13, up 0.70% from its previous closing price of $580.05. In other words, the price has increased by $+4.08 from its previous closing price. On the day, 1230506 shares were traded.
Ratios:
To gain a deeper understanding of TMO’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 27.56 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 32.15. For the most recent quarter (mrq), Quick Ratio is recorded 1.39 and its Current Ratio is at 1.75. In the meantime, Its Debt-to-Equity ratio is 0.78 whereas as Long-Term Debt/Eq ratio is at 0.70.
On January 24, 2024, Barclays Downgraded its rating to Equal Weight which previously was Overweight and also upped its target price recommendation from $475 to $555.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 13 ’24 when CASPER MARC N sold 10,000 shares for $594.58 per share. The transaction valued at 5,945,759 led to the insider holds 123,816 shares of the business.
Britt Lisa P. sold 14,345 shares of TMO for $8,591,220 on Mar 12 ’24. The Sr. VP and Chief HR Officer now owns 17,323 shares after completing the transaction at $598.90 per share. On Mar 12 ’24, another insider, CASPER MARC N, who serves as the Chairman & CEO of the company, sold 10,000 shares for $597.98 each. As a result, the insider received 5,979,758 and left with 123,816 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMO now has a Market Capitalization of 222.74B and an Enterprise Value of 249.58B. As of this moment, Thermo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 37.81, and their Forward P/E ratio for the next fiscal year is 24.10. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.61. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.20 while its Price-to-Book (P/B) ratio in mrq is 4.83. Its current Enterprise Value per Revenue stands at 5.82 whereas that against EBITDA is 22.53.
Stock Price History:
Over the past 52 weeks, TMO has reached a high of $603.82, while it has fallen to a 52-week low of $415.60. The 50-Day Moving Average of the stock is 562.37, while the 200-Day Moving Average is calculated to be 524.03.
Shares Statistics:
It appears that TMO traded 1.57M shares on average per day over the past three months and 1.34M shares per day over the past ten days. A total of 386.65M shares are outstanding, with a floating share count of 380.62M. Insiders hold about 0.18% of the company’s shares, while institutions hold 92.02% stake in the company. Shares short for TMO as of Feb 29, 2024 were 2.94M with a Short Ratio of 1.87, compared to 2.88M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.77% and a Short% of Float of 0.77%.
Dividends & Splits
With its trailing 12-month dividend rate of 1.40, TMO has a forward annual dividend rate of 1.44. Against a Trailing Annual Dividend Yield of 0.24%, it implies a Forward Annual Dividend Yield of 0.27%. The stock’s 5-year Average Dividend Yield is 0.22. The current Payout Ratio is 9.06% for TMO, which recently paid a dividend on Apr 15, 2024 with an ex-dividend date of Mar 14, 2024. Stock splits for the company last occurred on Jun 06, 1996 when the company split stock in a 3:2 ratio.
Earnings Estimates
As of right now, 20 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $4.73 for the current quarter, with a high estimate of $5 and a low estimate of $4.64, while EPS last year was $5.03. The consensus estimate for the next quarter is $5.13, with high estimates of $5.36 and low estimates of $4.99.
Analysts are recommending an EPS of between $21.9 and $21.31 for the fiscal current year, implying an average EPS of $21.58. EPS for the following year is $24.15, with 25 analysts recommending between $25.32 and $22.25.
Revenue Estimates
In the current quarter, 18 analysts expect revenue to total $10.19B. It ranges from a high estimate of $10.43B to a low estimate of $10.09B. As of the current estimate, Thermo Fisher Scientific Inc.’s year-ago sales were $10.71B, an estimated decrease of -4.80% from the year-ago figure. For the next quarter, 18 analysts are estimating revenue of $10.5B, a decrease of -4.40% over than the figure of -$4.80% in the same quarter last year. There is a high estimate of $10.78B for the next quarter, whereas the lowest estimate is $10.22B.
Based on 24 analysts’ estimates, the company’s revenue will be $45.94B in the next fiscal year. The high estimate is $46.88B and the low estimate is $45.16B. The average revenue growth estimate for next year is up 7.20% from the average revenue estimate for this year.
